eligibility_summary
Include: 18–75, relapsed/refractory mesothelin‑positive solid tumor, measurable disease, ECOG 0–1, life expectancy ≥3 mo, adequate organ function, negative pregnancy test/contraception, consent. Exclude: recent therapy/vaccines/trials, pregnant/lactating, active HBV/HCV/HIV/syphilis, unresolved AEs, prior transplant or anti‑MSLN CAR‑T, recent major surgery, unstable CNS mets, major infection/cardiac/autoimmune risks, severe drug allergy, other cancer <5 y, major psych disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05775666. Intervention: UCLM802, an autologous anti-mesothelin CAR-T cell therapy (biological). Mechanism: Patient T cells are genetically modified to express a chimeric antigen receptor that binds mesothelin (MSLN) on tumor cells, triggering T‑cell activation and cytotoxic killing of MSLN‑positive cancers. Conditioning: Lymphodepletion with fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent) to enhance CAR‑T expansion/persistence. Targets: Mesothelin-expressing tumor cells in solid tumors (e.g., mesothelioma, GI, ovarian, lung, etc.). Pathways/cells: Mesothelin antigen on tumor surface, CAR signaling in autologous T cells driving effector cytotoxicity within the tumor microenvironment. Phase 1, single-arm dose escalation/expansion.